Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | AOC2 | O75106 | 5/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222682 | 0.80 | CA2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28252353 | 0.80 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3971528 | 0.80 | CA2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5722725 | 0.80 | CA2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4828488 | 0.80 | CA2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17891950 | 0.79 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4704700 | 0.76 | MAOA (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1552025 | 0.76 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL36938 | 0.75 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7424079 | 0.75 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644591-A1 | Optically active 2-aryl cyclopropane carboxamide intermediates | Astrazeneca AB (SE) | 2013-10-02 | — | — | EP | disclosed |
| US-8278475-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2012-10-02 | — | — | US | disclosed |
| US-20120136167-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2012-05-31 | — | — | US | disclosed |
| US-8026396-B2 | Processes for the preparation of optically active intermediates | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20100331575-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-7790927-B2 | Using hypochlorite in water in presence of alkali metal hydroxide | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| EP-2049463-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | disclosed |
| WO-2008018823-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071114-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | CHRM2 1964/4885CHRM4 1546/4885CHRM5 1237/4885 |
| US-20100331575-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP1B1, CYP2S1 | CHRM2 1964/4885CHRM4 1546/4885CHRM5 1237/4885 |
| US-20120136167-A1 | Processes For The Preparation Of Optically Active Intermediates | DHPS, CYP2S1, CYP1B1 | CHRM2 1902/4885CHRM4 1516/4885CHRM5 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.